13F-HR: GSK plc Files 13F Holdings Report for Q1 2026
13F Holdings Report
GSK plc has filed its quarterly 13F holdings report, detailing its equity investments as of March 31, 2026.
Summary
- GSK plc, an institutional investment manager, has submitted its Form 13F for the quarter ended March 31, 2026.
- The report lists a total of 13 equity holdings.
- The total market value of these holdings is $599,153,380.
- All holdings are reported under the sole discretion of GSK plc.
- The filing does not indicate any amendments or restatements from previous reports.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of investment holdings without new strategic announcements or performance data.
Future Outlook
This filing is a snapshot of holdings as of a specific date and does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that this 13F filing from GSK plc provides a view into its significant equity investments in the biotechnology and pharmaceutical sectors, reflecting potential strategic interests or diversification within the healthcare industry.
Key Dates
| Date | Description |
|---|---|
| 03-31-2026 | Quarter End Date for the 13F Holdings Report |
| 05-09-2026 | Date of Signing for the 13F Holdings Report |
Keywords
13F Holdings Report, GSK plc, Equity Investments, Institutional Investment Manager, SEC Filing, Form 13F, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.